Lymphocytic choriomeningitis virus (LCMV) represents a useful experimental model of murine infection with a non-cytopathic virus, bearing resemblance to HIV and hepatitis C virus (HCV) infections in humans. Recent data from the LCMV model indicate that the humoral immune response that is induced by non-cytopathic viruses is far more complex than previously appreciated. LCMV-induced IgG production is largely polyclonal, with more than 90% of the antibody repertoire constituting non-relevant specificities. A delayed virusneutralizing antibody response is induced, including specificities directed not only against the parental LCMV-strain present in the host but also cross-specifically against LCMVvariants isolated from other hosts. These findings provide novel insights to aid our understanding of clinically relevant observations that are recorded following human infection with HIV, HCV and dengue viruses.
Neutralizing antibody-escape variantsDespite their late appearance, neutralizing antibodies represent a very effective means of controlling persistent infections with poorly or non-cytopathic viruses. Indeed, studies of simian immunodeficiency virus (SIV) infection in macaques or LCMV infection of mice have demonstrated that the passive transfer of monoclonal neutralizing antibody before viral infection results in rapid viral clearance and protection from a productive infection [30,31]. Neutralizing antibodies can also act to prevent CTL exhaustion and the emergence of CTL-escape variants, by virtue of their ability to limit viral replication [32,33]. The formation of neutralizing antibody-escape variants can be demonstrated by the ability of the host serum to neutralize the parental viral strain (used to inoculate the host) but not virus recovered from the host at later time-points [21]. This finding presents a great concern for clinical diagnosis of chronic viral infections; most current technologies use monoclonal antibodies directed against the parental viral strain for viral detection, and therefore do not account for the possible emergence of antibody-escape variants [34].The emergence of neutralizing antibody-escape variants has been most widely studied in LCMV infection of murine hosts. Using this model, experiments can be performed in which pressure on the virus to develop neutralizing antibody-escape variants is enhanced through infection of CD8 À/À mice [21]. These mice exhibit a high initial rate of LCMV replication as a consequence of the absent CTL response; however, between days 40-60 post-infection, neutralizing antibodies are generated and blood virus titers drop, indicating viral control. In these mice, pressure on the virus to develop escape mutants is mainly provided by the neutralizing antibody response and not by CTL activity (because CD8 + T cells are missing). Accordingly, by day 80 post-infection, neutralizing antibody-escape variants can be subcloned from the blood of CD8 À/À mice, and these correlate with viral re-emergence (Figure 1). Such antibody-escape variants have been shown to po...